Abound Bio | People

PEOPLE

Unmatched Expertise

Abound Bio was founded by renowned experts with a track-record of success and vast depth of knowledge. Supported by a team of highly skilled scientists, Dr. John Mellors and Dr. Dimiter Dimitrov bring unique and complementary skillsets highly desired by the biopharmaceutical industry.

Management Team

John Mellors, MD

PRESIDENT AND CHIEF EXECUTIVE OFFICER

Dimiter Dimitrov, PhD, ScD

EXECUTIVE VICE PRESIDENT AND CHIEF SCIENTIFIC OFFICER

Kurt Gehlsen, PhD

Consultant, Strategic and Business Development

Rimas Orentas, PhD

VP Cellular Therapy

Team

Cynthia Adams, MSc

Director of Pre-Clinical Development, Scientist I

Alex Conard, MBA, MS

Laboratory Management Director, Scientist I

Hyeyoung Eom, PhD

Scientist I

Chiquita Hanindya

Laboratory Technician

Gabriella Merritt

Director of Operations

Eric Peterson

Scientist I

Maria Singarayan, MS

Computational Biologist

Marcin Ura, PhD

Scientist II

Haiyang Zheng

Associate Scientist I

John Mellors, MD

PRESIDENT AND CHIEF EXECUTIVE OFFICER

Dr. Mellors is Chief of Infectious Diseases and Distinguished Professor at the University of Pittsburgh and UPMC. As Division Chief, he manages over 200 personnel. He has over 30 years of experience in laboratory science, clinical investigation and consultation for pharmaceutical development. He has published more than 400 publications and multiple patents. He is co-founder of Infectious Disease Connect, a telemedicine company specializing in diagnosis, treatment and prevention of infectious diseases.

Dimiter Dimitrov, PhD, ScD

Executive Vice President and Chief Scientific Officer

Dr. Dimitrov is a world-leading antibody scientist and engineer with more than 30 years of experience. He was tenured Senior Investigator in the National Cancer Institute and appointed at the Senior Biomedical Research Service at the NIH; currently he is Professor of Medicine and Director of the Center for Antibody Therapeutics at the University of Pittsburgh Medical School. He has over 400 publications, 100 patents, and multiple discoveries leading to one therapeutic antibody approval, several others in multiple clinical trials, and many more in preclinical development.

Kurt Gehlsen

Consultant, Strategic and Business Development

Highly experienced senior executive with 30+ year’s experience in private and public companies, company formation and growth, technology and company investments, pharmaceutical and medical device product development, basic research, clinical development, regulatory affairs, strategic planning, business development, licensing, project management, investor relations and executive management.

Rimas Orentas, PhD

VP Cellular Therapy

Dr. Orentas is a leader in CAR-T cell biology and the genetic engineering of immune effector cells. He has 30 years experience in academia, NIH, and private sector. He has developed five first-in-human CAR-T cell products including best-in-class CD22 and tandem CD19-20.